PepGen R&D Spending Growth & History (PEPG)
PepGen's r&d spending was $71.0M for fiscal 2025.
View full PepGen company overviewPepGen annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $71.0M | −$5.4M | −7.11% |
| 2024 | 2024-12-31 | $76.5M | $8.4M | +12.26% |
| 2023 | 2023-12-31 | $68.1M | $14.0M | +25.98% |
| 2022 | 2022-12-31 | $54.1M | $35.1M | +184.63% |
| 2021 | 2021-12-31 | $19.0M | — | — |
PepGen quarterly r&d spending
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $12.5M | −$5.9M | −31.91% |
| Q1 2026 | 2026-03-31 | $13.0M | −$12.4M | −48.76% |
| Q4 2025 | 2025-12-31 | $13.9M | −$5.1M | −26.95% |
| Q3 2025 | 2025-09-30 | $13.4M | −$4.3M | −24.26% |
| Q2 2025 | 2025-06-30 | $18.4M | −$6.7M | −26.62% |
| Q1 2025 | 2025-03-31 | $25.4M | $10.6M | +72.26% |
| Q4 2024 | 2024-12-31 | $19.0M | $2.7M | +16.33% |
| Q3 2024 | 2024-09-30 | $17.7M | −$2.8M | −13.72% |
| Q2 2024 | 2024-06-30 | $25.1M | $8.1M | +48.07% |
| Q1 2024 | 2024-03-31 | $14.7M | $372,000 | +2.59% |
| Q4 2023 | 2023-12-31 | $16.3M | $3.1M | +23.80% |
| Q3 2023 | 2023-09-30 | $20.5M | $4.6M | +28.66% |
| Q2 2023 | 2023-06-30 | $16.9M | $2.7M | +18.86% |
| Q1 2023 | 2023-03-31 | $14.4M | $3.7M | +34.12% |
| Q4 2022 | 2022-12-31 | $13.2M | $8.6M | +189.94% |
| Q3 2022 | 2022-09-30 | $16.0M | $10.3M | +179.48% |
| Q2 2022 | 2022-06-30 | $14.2M | $11.0M | +342.79% |
| Q1 2022 | 2022-03-31 | $10.7M | $5.2M | +93.62% |
| Q4 2021 | 2021-12-31 | $4.5M | — | — |
| Q3 2021 | 2021-09-30 | $5.7M | — | — |
| Q2 2021 | 2021-06-30 | $3.2M | — | — |
| Q1 2021 | 2021-03-31 | $5.5M | — | — |
PepGen r&d spending trends
Between the periods ended 2021-12-31 and 2025-12-31, PepGen's r&d spending increased from $19.0M to $71.0M, a change of $52.0M. The latest reported quarter, Q2 2026, shows $12.5M.
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review PepGen source filings ↗Community posts
Novartis’ DM1 trial misses its primary endpoint
Novartis’ ($NVS) del-desiran failed to show a statistically significant improvement on the primary endpoint in the Phase III HARBOR trial for myotonic dystrophy type 1. The company will continue analysing the data and discuss next steps wit ...